Deutsche Bank AG reduced its stake in shares of CryoPort Inc (NASDAQ:CYRX) by 58.1% during the 4th quarter, Holdings Channel reports. The fund owned 33,762 shares of the consumer goods maker’s stock after selling 46,881 shares during the period. Deutsche Bank AG’s holdings in CryoPort were worth $371,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Metropolitan Life Insurance Co. NY increased its stake in CryoPort by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,607 shares of the consumer goods maker’s stock worth $95,000 after acquiring an additional 6,722 shares during the last quarter. MML Investors Services LLC bought a new stake in CryoPort during the fourth quarter worth approximately $157,000. Bank of America Corp DE increased its stake in CryoPort by 92.3% during the fourth quarter. Bank of America Corp DE now owns 16,037 shares of the consumer goods maker’s stock worth $176,000 after acquiring an additional 7,697 shares during the last quarter. MetLife Investment Advisors LLC increased its stake in CryoPort by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 18,910 shares of the consumer goods maker’s stock worth $242,000 after acquiring an additional 6,722 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in CryoPort by 50.1% during the fourth quarter. Rhumbline Advisers now owns 33,919 shares of the consumer goods maker’s stock worth $374,000 after acquiring an additional 11,321 shares during the last quarter. 52.87% of the stock is currently owned by institutional investors.
CYRX has been the topic of several analyst reports. BidaskClub raised CryoPort from a “hold” rating to a “buy” rating in a research note on Tuesday, March 19th. ValuEngine raised CryoPort from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 31st. Four investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $19.75.
In other news, Director Richard J. Berman sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $11.84, for a total transaction of $355,200.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 11.00% of the company’s stock.
CYRX opened at $17.38 on Friday. The company has a market cap of $533.15 million, a PE ratio of -56.06 and a beta of 1.10. CryoPort Inc has a one year low of $8.28 and a one year high of $18.11. The company has a current ratio of 11.57, a quick ratio of 11.52 and a debt-to-equity ratio of 0.42.
CryoPort (NASDAQ:CYRX) last released its earnings results on Thursday, May 2nd. The consumer goods maker reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08). The firm had revenue of $6.65 million for the quarter, compared to analysts’ expectations of $6.56 million. CryoPort had a negative return on equity of 28.30% and a negative net margin of 41.61%. The company’s quarterly revenue was up 65.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.10) earnings per share. As a group, equities research analysts predict that CryoPort Inc will post -0.3 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Deutsche Bank AG Has $371,000 Holdings in CryoPort Inc (CYRX)” was originally reported by Stock Observer and is the property of of Stock Observer. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2019/05/25/deutsche-bank-ag-has-371000-holdings-in-cryoport-inc-cyrx.html.
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Featured Article: Why Invest in Dividend Achievers?
Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoPort Inc (NASDAQ:CYRX).
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.